Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report

<h3>Abstract</h3><p dir="ltr">Although Burkitt lymphoma is considered a curable disease due to the progress made in choosing the most effective first-line therapy, relapsed or refractory Burkitt lymphoma (BL) has a very poor outcome. There is a lack of data supporting the treatment regimens. We report a 48-year-old male with stage II Burkitt’s lymphoma with no response to the first line of high-intensity chemotherapy. However, treatment with polatuzumab vedotin led to complete clinical remission for more than one year.</p><h2>Other Information</h2><p dir="ltr">Published in: OncoTargets and Therapy<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.2147/ott.s394193" target="_blank">https://dx.doi.org/10.2147/ott.s394193</a></p>